Drugs in Dev. Oncology
Undisclosed
Japan 
Lead Product(s) : 225-Ac PET
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Cyclotron
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ac-225, a core material used for TAT, a new therapeutic concept to attack cancer cells in body, applying a therapeutic agent in which alpha particle-emitting radionuclides that can kill cancer cells are bound to antibodies selectively accumulated in prot...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 04, 2022
Lead Product(s) : 225-Ac PET
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Cyclotron
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Merck & Co
Deal Size : $2,550.0 million
Deal Type : Collaboration
Merck Establishes Strategic Oncology Collaboration with Taiho and Astex
Details : Under the terms of the agreement, Merck, Taiho and Astex will combine preclinical candidates and their data with knowledge and expertise from their respective research programs.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $50.0 million
June 01, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Merck & Co
Deal Size : $2,550.0 million
Deal Type : Collaboration
Lead Product(s) : Datopotamab Deruxtecan,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Strategic research collaboration aims at to evaluating the combination of DS-1062, a TROP2 directed DXd antibody drug conjugate, and KEYTRUDA in patients with previously-treated advanced or metastatic non-small cell lung cancer without actionable genomic...
Product Name : DS-1062a
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
May 29, 2020
Lead Product(s) : Datopotamab Deruxtecan,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Reset All
